Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer

Science

Volumn 283, Issue 5398, 1999, Pages 88-91

  Ye, Xuehai ^a   Rivera, Victor M ^b   Zoltick, Philip ^a   Cerasoli Jr , Franklin ^b   Schnell, Michael A ^a   Gao, Guang Ping ^a   Hughes, Joseph V ^a   Gilman, Michael ^b   Wilson, James M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b ARIAD PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; RAPAMYCIN;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE TARGETING; GENE THERAPY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN TARGETING; SOMATIC CELL;

ANIMALS; CYTOMEGALOVIRUS; DEPENDOVIRUS; ERYTHROPOIETIN, RECOMBINANT; FEMALE; GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEMATOCRIT; INJECTIONS, INTRAMUSCULAR; MACACA MULATTA; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MUSCLE, SKELETAL; PROMOTER REGIONS (GENETICS); RECOMBINANT FUSION PROTEINS; SIROLIMUS; TRANSCRIPTION FACTORS;

ADENO-ASSOCIATED VIRUS; ANIMALIA; MACACA MULATTA; MUS MUSCULUS;

EID: 0032949030     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.283.5398.88     Document Type: Article

References (31)

1. R. O. Snyder et al., Hum. Gene Ther. 8, 1891 (1997); S. K. Tripathy et al., Proc. Natl. Acad. Sci. U.S.A. 93, 10876 (1996); N. Naffakh et al., Hum. Gene Ther. 7, 11 (1996); R. O. Snyder et al., Nature Genet. 8, 270 (1997); S. Connelly, J. M. Gardner, R. M. Lyons, A. McClelland, M. Kaleko, Blood 87, 4671 (1996); P. Moullier, D. Bohl, J. M. Heard, O. Danos, Nature Genet. 4, 154 (1993).
2. R. O. Snyder et al., Hum. Gene Ther. 8, 1891 (1997); S. K. Tripathy et al., Proc. Natl. Acad. Sci. U.S.A. 93, 10876 (1996); N. Naffakh et al., Hum. Gene Ther. 7, 11 (1996); R. O. Snyder et al., Nature Genet. 8, 270 (1997); S. Connelly, J. M. Gardner, R. M. Lyons, A. McClelland, M. Kaleko, Blood 87, 4671 (1996); P. Moullier, D. Bohl, J. M. Heard, O. Danos, Nature Genet. 4, 154 (1993).
3. R. O. Snyder et al., Hum. Gene Ther. 8, 1891 (1997); S. K. Tripathy et al., Proc. Natl. Acad. Sci. U.S.A. 93, 10876 (1996); N. Naffakh et al., Hum. Gene Ther. 7, 11 (1996); R. O. Snyder et al., Nature Genet. 8, 270 (1997); S. Connelly, J. M. Gardner, R. M. Lyons, A. McClelland, M. Kaleko, Blood 87, 4671 (1996); P. Moullier, D. Bohl, J. M. Heard, O. Danos, Nature Genet. 4, 154 (1993).
4. R. O. Snyder et al., Hum. Gene Ther. 8, 1891 (1997); S. K. Tripathy et al., Proc. Natl. Acad. Sci. U.S.A. 93, 10876 (1996); N. Naffakh et al., Hum. Gene Ther. 7, 11 (1996); R. O. Snyder et al., Nature Genet. 8, 270 (1997); S. Connelly, J. M. Gardner, R. M. Lyons, A. McClelland, M. Kaleko, Blood 87, 4671 (1996); P. Moullier, D. Bohl, J. M. Heard, O. Danos, Nature Genet. 4, 154 (1993).
5. R. O. Snyder et al., Hum. Gene Ther. 8, 1891 (1997); S. K. Tripathy et al., Proc. Natl. Acad. Sci. U.S.A. 93, 10876 (1996); N. Naffakh et al., Hum. Gene Ther. 7, 11 (1996); R. O. Snyder et al., Nature Genet. 8, 270 (1997); S. Connelly, J. M. Gardner, R. M. Lyons, A. McClelland, M. Kaleko, Blood 87, 4671 (1996); P. Moullier, D. Bohl, J. M. Heard, O. Danos, Nature Genet. 4, 154 (1993).
6. R. O. Snyder et al., Hum. Gene Ther. 8, 1891 (1997); S. K. Tripathy et al., Proc. Natl. Acad. Sci. U.S.A. 93, 10876 (1996); N. Naffakh et al., Hum. Gene Ther. 7, 11 (1996); R. O. Snyder et al., Nature Genet. 8, 270 (1997); S. Connelly, J. M. Gardner, R. M. Lyons, A. McClelland, M. Kaleko, Blood 87, 4671 (1996); P. Moullier, D. Bohl, J. M. Heard, O. Danos, Nature Genet. 4, 154 (1993).
7. D. Bohl and J. M. Heard, Hum. Gene Ther. 8, 195 (1997); D. Bohl, N. Naffakh, J. M. Heard, Nature Med. 3, 299 (1997); Y. Wang, J. Xu, T. Pierson, B. W. O'Malley, S. Y. Tsai, Gene Ther. 5, 432 (1997); Y. Wang, B. W. O'Malley Jr., S. Y. Tsai, B. W. O'Malley, Proc. Natl. Acad. Sci. U.S.A. 91, 8180 (1994); D. No, T. P. Yao, R. M. Evans, ibid. 93, 3346 (1996).
8. D. Bohl and J. M. Heard, Hum. Gene Ther. 8, 195 (1997); D. Bohl, N. Naffakh, J. M. Heard, Nature Med. 3, 299 (1997); Y. Wang, J. Xu, T. Pierson, B. W. O'Malley, S. Y. Tsai, Gene Ther. 5, 432 (1997); Y. Wang, B. W. O'Malley Jr., S. Y. Tsai, B. W. O'Malley, Proc. Natl. Acad. Sci. U.S.A. 91, 8180 (1994); D. No, T. P. Yao, R. M. Evans, ibid. 93, 3346 (1996).
9. D. Bohl and J. M. Heard, Hum. Gene Ther. 8, 195 (1997); D. Bohl, N. Naffakh, J. M. Heard, Nature Med. 3, 299 (1997); Y. Wang, J. Xu, T. Pierson, B. W. O'Malley, S. Y. Tsai, Gene Ther. 5, 432 (1997); Y. Wang, B. W. O'Malley Jr., S. Y. Tsai, B. W. O'Malley, Proc. Natl. Acad. Sci. U.S.A. 91, 8180 (1994); D. No, T. P. Yao, R. M. Evans, ibid. 93, 3346 (1996).
10. D. Bohl and J. M. Heard, Hum. Gene Ther. 8, 195 (1997); D. Bohl, N. Naffakh, J. M. Heard, Nature Med. 3, 299 (1997); Y. Wang, J. Xu, T. Pierson, B. W. O'Malley, S. Y. Tsai, Gene Ther. 5, 432 (1997); Y. Wang, B. W. O'Malley Jr., S. Y. Tsai, B. W. O'Malley, Proc. Natl. Acad. Sci. U.S.A. 91, 8180 (1994); D. No, T. P. Yao, R. M. Evans, ibid. 93, 3346 (1996).
11. D. Bohl and J. M. Heard, Hum. Gene Ther. 8, 195 (1997); D. Bohl, N. Naffakh, J. M. Heard, Nature Med. 3, 299 (1997); Y. Wang, J. Xu, T. Pierson, B. W. O'Malley, S. Y. Tsai, Gene Ther. 5, 432 (1997); Y. Wang, B. W. O'Malley Jr., S. Y. Tsai, B. W. O'Malley, Proc. Natl. Acad. Sci. U.S.A. 91, 8180 (1994); D. No, T. P. Yao, R. M. Evans, ibid. 93, 3346 (1996).
12. E. J. Brown et al., Nature 369, 756 (1994); R. F. Standaert, A. Galat, G. L. Verdine, S. L. Schrieber, ibid. 346, 671 (1990).
13. E. J. Brown et al., Nature 369, 756 (1994); R. F. Standaert, A. Galat, G. L. Verdine, S. L. Schrieber, ibid. 346, 671 (1990).
14. V. M. Rivera et al., Nature Med. 2, 1028 (1996); S. R. Magari, V. M. Rivera, J. D. Iuliucci, M. Gilman, F. Cerasoli Jr., J. Clin. Invest. 100, 2865 (1997).
15. V. M. Rivera et al., Nature Med. 2, 1028 (1996); S. R. Magari, V. M. Rivera, J. D. Iuliucci, M. Gilman, F. Cerasoli Jr., J. Clin. Invest. 100, 2865 (1997).
16. P. D. Kessler et al., Proc. Natl. Acad. Sci. U.S.A. 93, 14082 (1996); X. Xiao, J. Li, R. J. Samulski, J. Virol. 70, 8098 (1996).
17. P. D. Kessler et al., Proc. Natl. Acad. Sci. U.S.A. 93, 14082 (1996); X. Xiao, J. Li, R. J. Samulski, J. Virol. 70, 8098 (1996).
18. K. J. Fisher et al., Nature Med. 3, 306 (1997).
19. K. Jooss, Y. Yang, K. J. Fisher, J. M. Wilson, J. Virol. 72, 4212 (1998).
20. 2-terminal epitope tag from influenza virus hemagglutin and nuclear localization signal from SV40 large T antigen (4, 16). Reporter construct AAV.Z12mEpo3S3 contains the 12 ZFHD1-binding sites (4), a minimal interleukin-2 promoter (4), a chimeric intron from pCl vector (Promega), a murine Epo cDNA, an SV40 late gene 3′ UTR, and a 2.7-kb stuffer containing a 1367-bp internal portion of human placental alkaline phosphatase coding sequence followed by a 626-bp portion of the human growth hormone 3′ UTR and a 720-bp portion of the 3′ rabbit β-globin intron and PAS (4). Reporter construct AAV.Z12rmEpo2S2 is similar except that the Epo cDNA is derived from a rhesus monkey Epo and the vector lacks the chimeric intron and the 720-bp rabbit β-globin portion of the stuffer. Reporter construct AAV.CM-VrmEpo3 contains a human CMV enhancer-promoter, a chimeric intron from pCl vector, a rhesus monkey Epo cDNA, and an SV40 late gene 3′ UTR. Recombinant AAV was generated by cloning CMVTF1, Z12mEpo3S3, Z12rmEpo2S2, and CMVrmEpo3 expression cassettes into Xba I-restricted pSub 201 backbone (17). The resulting plasmids were used to produce recombinant AAV by a triple transfection method (18) or by an Ad/AAV hybrid system (17).
21. K. J. Fisher et al., J. Virol. 70, 520 (1996).
22. X. Ye et al., unpublished data.
23. G.-P. Gao et al., Hum. Gene Ther. 9, 2353 (1998).
24. 13 genomes per kilogram) peak Epo levels of 560 and 120 mU/ml.
25. Antibodies to the influenza virus hemagglutinin tag were detected in serum of the nonhuman primate 3 months after gene transfer, although it is unclear whether their presence predicts functional cellular immune responses.
26. K. G. Rendahl et al., Nature Biotechnol. 16, 757 (1998).
27. X. Ye et al., J. Biol. Chem. 271, 3639 (1996).
28. V. M. Rivera, Methods 14, 421 (1998).
29. R. J. Samulski, L.-S. Change, T. Shenk, J. Virol. 61, 3096 (1987).
30. W. Xiao, S. C. Berta, M.-M. Lu, J. Tazelaar, J. M. Wilson, ibid. 72, 10222 (1998).
31. Funding was provided by grants from the NIH [P30 DK47757-05 (J.M.W.) and P01 AR/NS43648-03 (H. L. Sweeney)], the Muscular Dystrophy Association, ARIAD Pharmaceuticals, and Genovo, a company J.M.W. founded and in which he holds equities. Technical support from N. Courage was greatly appreciated. W. Xiao provided plasmids for AAV production.